Abstract 919P
Background
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18F-FDG PET-CT) is a non-invasive imaging modality. This study aimed to investigate the effects of radiometric parameters and clinical characteristics of 18F-FDG PET-CT on the prognosis of patients with nasopharyngeal carcinoma (NPC).
Methods
A total of 801 patients with metastatic NPC were enrolled between 2016 and 2020, and all participants underwent 18F-FDG PET/CT before treatment. We assessed the following 18F-FDG PET parameters: standardized uptake value (SUV), SUV-avg (average), SUV-peak (maximum), and total lesion glycolysis (TLG) of the primary tumor and regional lymph nodes. We used multivariate Cox proportional hazards models and multiple machine learning techniques to identify independent predictors of survival based on radiomic parameters and patient clinical characteristics. After selecting the features, we established prognosis models using a COX stepwise regression model. Finally, we performed internal validation, and a nomogram was created for NPC comprehensive diagnosis.
Results
In this study, we developed a stable and robust model incorporating five independent prognostic features based on COX regression. The area under the curve (AUC) of the model was 0.75 (95% CI = 0.52–0.97) at 1 year, 0.80 (95% CI = 0.71–0.89) at 3 years, and 0.86 (95% CI = 0.78–0.94) at 5 years. The AUC at 3 years and 5 years were calculated as 0.7276 and 0.7242, respectively. The model was validated using receiver operating characteristic (ROC), consistency index, and multivariate analysis, which showed high accuracy and consistent performance. Moreover, patients in the low-risk score group exhibited significantly better outcomes than those in the high-risk score group (P < 0.001).
Conclusions
Our findings suggest that age, SUV-Tmax, SUV-Tavg, SUV-Tpeak, and TLG-T are valuable parameters for predicting long-term survival in patients with NPC. The nomogram based on metabolic parameters combined with other variables showed good prognostic accuracy in predicting NPC prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12